Evaluation of pulmonary lesions with FDG-PET: Comparison of findings in patients with and without a history of prior malignancy

Chest

Volumn 109, Issue 4, 1996, Pages 982-988

  Knight, Steven B ^a   Delbeke, Dominique ^a   Stewart, James R ^a   Sandler, Martin P ^a   Ebers, Tom ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

emission CT; fluorine; glucose, metabolism; lung, neoplasms

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INFLAMMATION; LUNG CANCER; LUNG DISEASE; LUNG GRANULOMA; LUNG TUBERCULOSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; NEURILEMOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0344828751     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.4.982     Document Type: Article

References (29)

1. Boring CC. Cancer statistics, 1991. CA 1991; 41:19-36
2. Stanley K, Stjernsward J. Lung cancer. In: Hansen HH, ed. Basic and clinical concepts of lung cancer. Norwell, Mass: Kluwer, 1989; 1-4
3. Warburg O. Versuche and uberlebeudem carcinomgewebe (methoden). Biochem Z 1923; 142:317-33
4. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes. Science 1987; 235:1492-95
5. Monakhov NK, Neistadt EI, Shaylovskii MM, et al. Physiochemical properties and isoenzyme composition of hexoldnase from normal and malignant human tissues. J Natl Cancer Inst 1978; 61:27-34
6. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation, and growth rates of transplanted tumors. Cancer Res 1970; 30:2240-44
7. Weber MJ, Nakamura KD, Salter DW. Molecular events leading to enhanced glucose transport in Rous sarcoma virus-transformed cells. Fed Proc 1984; 43:2246-50
8. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose [18F]: nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-75
9. Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:11.54-61
10. Wahl RL, Hutchins GD, Buschsbaum DJ, et al. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron emission tomography. Cancer 1991; 67:1544-50
11. Abe Y, Matsauzawa J, Fijiwaar T, et al. Clinical assessment of therapeutic effects on cancer using F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int J Radiat Oncol Biol Phys 1990; 19:1005-10
12. Kubota K, Matsauzawa J, Fijiwaar T, et al. Differential diagnosis of lung cancer with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-33
13. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human neoplasm. Cancer 1987; 60:2682-89
14. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184:441-44
15. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993; 104:997-1002
16. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18-fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-90
17. Patz E, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma using 18F-2-deoxy-D-glucose and positron emission tomography (PET) imaging. Radiology 1994; 191:379-84
18. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72:82-90
19. Chin R, Ward R, Keyes J, et al. PET-FDG imaging in the mediastinal staging of non-small cell lung cancer (NSCLC). Chest 1993; 104(suppl):120S
20. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with 18FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-77
21. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771-76
22. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: effect of object size. J Comput Assist Tomogr 1979; 3:299-308
23. Mazziotta JC, Phelps ME, Plummer D, et al. Quantitation in positron emission tomography: V. Physical-anatomical effects. J Comput Assist Tomogr 1981; 5:737-43
24. Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scun data: limitation imposed by resolution and background. J Comput Assist Tomogr 1984; 8:514-22
25. Langen KJ, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355-59
26. Kini CK, Gupta NC, Chandramouli B, et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994; 35:164-67
27. Hubner KF, Buonocore E, Singh SK, et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 1995; 20:293-98
28. Dewan NA, Gupta NC. Potential cost-savings utilizing PET-FDG imaging in the evaluation and management of solitary pulmonary nodules. Chest 1993; 104(suppl):120S
29. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-06